摘要
目的探讨对冠心病心绞痛患者采用伊伐布雷定治疗的临床效果及对改善患者左心室功能的作用。方法选择2018年1月—2021年5月收治冠心病心绞痛者90例,随机分为常规采用酒石酸美托洛尔治疗的对照组(n=45)与联合使用伊伐布雷定治疗的研究组(n=45),对比两组临床疗效、治疗后心绞痛发作次数、持续时间,并评价两组左心室功能指标(LVEF、LVEDD、LVESV),并统计两组不良反应发生率。结果研究组治疗后总有效率为95.56%,高于对照组80.00%,差异有统计学意义(χ^(2)=5.075,P<0.05)。治疗后研究组心绞痛发作次数、持续时间分别为(1.10±0.45)次/d、(3.37±1.14)min,均小于对照组(1.76±0.54)次/d、(7.26±2.01)min,差异有统计学意义(t=6.299、11.293,P<0.05)。研究组治疗后LVEF、LVEDD、LVESV分别为(39.64±5.04)%、(57.11±4.25)mm、(61.97±17.48)mL,LVEF大于对照组,LVEDD、LVESV小于对照组,差异有统计学意义(t=2.973、3.113、2.621,P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论对冠心病心绞痛患者,通过联合使用伊伐布雷定能提高临床疗效与改善患者症状,且能促进患者左心室功能的改善,用药安全可靠,值得推广。
Objective To explore the clinical effect of ivabradine treatment in patients with coronary heart disease and angina pectoris and its effect on improving the left ventricular function of patients.Methods From January 2018 to May 2021,90 patients with coronary heart disease and angina pectoris were selected and randomly divided into a control group(n=45)treated with metoprolol tartrate and an study group treated with ivabradine(n=45).The clinical efficacy,number and duration of angina pectoris after treatment were compared between the two groups,and the left ventricular function indicators of the two groups was evaluated(LVEF,LVEDD,LVESV),and the incidence of adverse reactions between the two groups was analyzed.Results The total effective rate after treatment in the study group was 95.56%,which was higher than 80.00% in the control group,the difference was statistically significant(χ^(2)=5.075,P<0.05).After treatment,the number and duration of angina pectoris in the study group were(1.10±0.45)times/d and(3.37±1.14)min,which were less than those in the control group(1.76±0.54)times/d and(7.26±2.01)min,the difference was statistically significant(t=6.299,11.293,P<0.05).After treatment,LVEF,LVEDD,and LVESV of the study group were(39.64±5.04)%,(57.11±4.25)mm,and(61.97±17.48)mL,respectively,and the LVEF was greater than that of the control group.LVEDD and LVESV were lower than the control group,the difference was statistically significant(t=2.973,3.113,2.621,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with coronary heart disease and angina pectoris,the combined use of ivabradine can improve the clinical efficacy and improve the symptoms of patients,and can promote the improvement of patients'left ventricular function.The medication is safe and reliable,and it is worthy of promotion.
作者
周天坤
翟雨阳
ZHOU Tiankun;ZHAI Yuyang(Department of Cardiovascular Medicine,People's Hospital of Liuhe District,Nanjing,Yangzhou University,Nanjing,Jiangsu Province,211500 China)
出处
《系统医学》
2021年第22期106-109,共4页
Systems Medicine
基金
南京市2016年度科技发展计划项目(201605071)。
关键词
冠心病
心绞痛
左心室功能
伊伐布雷定
酒石酸美托洛尔
Coronary heart disease
Angina pectoris
Left ventricular function
Ivabradine
Metoprolol tartrate
